REGENXBIO Inc. (RGNX)Healthcare | Biotechnology | Rockville, United States | NasdaqGS
12.29 USD
-0.46
(-3.608%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:43 a.m. EDT
The fundamental picture is dire: revenue has collapsed by nearly 93%, the company is burning cash with negative free cash flow, and the balance sheet is fragile with debt significantly exceeding equity. While the recent price action shows a sharp bounce off the lows, this appears to be a technical relief rally rather than a reversal of the multi-year downtrend, which has seen seven consecutive years of decline. The options market confirms this pessimism, with traders stacking protection via deep in-the-money puts rather than betting on upside. Although the FDA regulatory win offers a glimmer of hope for the pipeline, the financial reality suggests the company is in survival mode. Investors should view this as a high-risk speculative play on a turnaround, not a value investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.194605 |
| AutoETS | 0.232902 |
| MSTL | 0.242944 |
| AutoTheta | 0.245946 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 6.69 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.155 |
| Excess Kurtosis | -1.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1178.237 |
| Revenue per Share | 1.694 |
| Market Cap | 635,363,776 |
| Forward P/E | -4.77 |
| Beta | 0.90 |
| Website | https://www.regenxbio.com |
As of July 11, 2026, 6:43 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated deep in-the-money (strikes below $10), while call activity remains thin and mostly at-the-money. The massive IV spike on far-dated out-of-the-money calls suggests fear of a binary event, but the lack of corresponding call volume indicates the market is not pricing in a rally, only a potential collapse or stagnation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.54733014 |
| Address1 | 9,804 Medical Center Drive |
| All Time High | 85.1 |
| All Time Low | 5.035 |
| Ask | 15.64 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.5 - Buy |
| Average Daily Volume10 Day | 2,780,460 |
| Average Daily Volume3 Month | 1,980,375 |
| Average Volume | 1,980,375 |
| Average Volume10Days | 2,780,460 |
| Beta | 0.901 |
| Bid | 9.31 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.408 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.29 |
| Current Ratio | 2.623 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 13.0 |
| Day Low | 12.18 |
| Debt To Equity | 1,178.237 |
| Display Name | REGENXBIO |
| Earnings Call Timestamp End | 1,778,765,400 |
| Earnings Call Timestamp Start | 1,778,765,400 |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -241,170,000 |
| Ebitda Margins | -2.74612 |
| Enterprise To Ebitda | -3.04 |
| Enterprise To Revenue | 8.349 |
| Enterprise Value | 733,268,736 |
| Eps Current Year | -2.82362 |
| Eps Forward | -2.57471 |
| Eps Trailing Twelve Months | -5.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.9873 |
| Fifty Day Average Change | 3.3027 |
| Fifty Day Average Change Percent | 0.36748523 |
| Fifty Two Week Change Percent | 54.733013 |
| Fifty Two Week High | 16.19 |
| Fifty Two Week High Change | -3.9000006 |
| Fifty Two Week High Change Percent | -0.24088946 |
| Fifty Two Week Low | 5.455 |
| Fifty Two Week Low Change | 6.835 |
| Fifty Two Week Low Change Percent | 1.2529789 |
| Fifty Two Week Range | 5.455 - 16.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,496,600,000 |
| Float Shares | 43,043,956 |
| Forward Eps | -2.57471 |
| Forward P E | -4.773353 |
| Free Cashflow | -138,978,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 371 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.9660801 |
| Gross Profits | -172,664,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08063 |
| Held Percent Institutions | 0.81927 |
| Implied Shares Outstanding | 51,697,621 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. |
| Long Name | REGENXBIO Inc. |
| Market | us_market |
| Market Cap | 635,363,776 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_130641748 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -290,012,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 659,403,155 |
| Number Of Analyst Opinions | 11 |
| Open | 12.8011 |
| Operating Cashflow | -233,778,000 |
| Operating Margins | -13.03957 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 240 552 8181 |
| Pre Market Change | 0.10000038 |
| Pre Market Change Percent | 0.8136728 |
| Pre Market Price | 12.39 |
| Pre Market Time | 1,784,102,404 |
| Previous Close | 12.75 |
| Price Eps Current Year | -4.3525686 |
| Price Hint | 2 |
| Price To Book | 30.12255 |
| Price To Sales Trailing12 Months | 7.234677 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.445 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.54545 |
| Region | US |
| Regular Market Change | -0.46000004 |
| Regular Market Change Percent | -3.6078434 |
| Regular Market Day High | 13.0 |
| Regular Market Day Low | 12.18 |
| Regular Market Day Range | 12.18 - 13.0 |
| Regular Market Open | 12.8011 |
| Regular Market Previous Close | 12.75 |
| Regular Market Price | 12.29 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 1,574,285 |
| Return On Assets | -0.38527 |
| Return On Equity | -1.96433 |
| Revenue Growth | -0.928 |
| Revenue Per Share | 1.694 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 51,697,621 |
| Shares Percent Shares Out | 0.2023 |
| Shares Short | 10,459,575 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,281,637 |
| Short Name | REGENXBIO Inc. |
| Short Percent Of Float | 0.2177 |
| Short Ratio | 4.53 |
| Source Interval | 15 |
| State | MD |
| Symbol | RGNX |
| Target High Price | 50.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 24.36364 |
| Target Median Price | 19.0 |
| Total Cash | 150,491,008 |
| Total Cash Per Share | 2.911 |
| Total Debt | 248,396,000 |
| Total Revenue | 87,822,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.5746 |
| Two Hundred Day Average Change | 1.7153997 |
| Two Hundred Day Average Change Percent | 0.16221887 |
| Type Disp | Equity |
| Volume | 1,574,285 |
| Website | https://www.regenxbio.com |
| Zip | 20,850 |